It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes proportion of patients achieving clinical remission compared with placebo oil (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether anti‐TB therapy changes relapse compared with placebo (very low certainty).
It is very uncertain whether anti‐TB therapy changes adverse events compared with placebo (very low certainty).
It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission compared with placebo (moderate certainty).
Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to higher clinical remission compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to higher mucosal healing compared with infliximab (moderate certainty).
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission1 compared with methotrexate (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission or improvement compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes clinical remission compared with 5‐ASA or Sulfasalzine (very low certainty).